VBI Vaccines Secures Lucrative Contract and Makes Noteworthy Developments

 As of June 30, 2023, VBI Vaccines has secured a lucrative contract worth $25.35 million from the Department of Health and Human Services for the production of “2023 Adult Vaccines.”

In addition to this significant achievement, VBI Vaccines has been involved in various other noteworthy developments:

1. A groundbreaking license and collaboration agreement has been established between VBI Vaccines and Brii Biosciences. This partnership entails an investment of up to $129 million, along with royalties, with the aim of developing a functional cure for Hepatitis B.

2. VBI Vaccines has joined forces with Resilience to facilitate the development and manufacturing services required for the production of its coronavirus vaccine candidates. This collaboration is crucial in ensuring the timely and efficient delivery of these potential vaccines.

3. Recognizing the importance of combating Hepatitis B, VBI Vaccines has announced an intensified focus on this disease. This strategic shift has prompted organizational changes and a reverse stock split, demonstrating their commitment to addressing this global health concern.

4. VBI Vaccines has recently signed a first amendment to their collaborative research agreement, specifically targeting the development of therapeutics, vaccines, and emerging infections that impact human health. This amendment signifies their dedication to advancing medical breakthroughs in these crucial areas.

5. To further enhance their commercial capabilities, VBI Vaccines has entered into a master commercial services agreement with inVentiv Commercial Services, LLC. This partnership will enable VBI Vaccines to leverage inVentiv’s expertise and resources for the successful commercialization of their products.

6. As part of their commitment to transparency and compliance, VBI Vaccines has filed a Form 10-K with the United States Securities and Exchange Commission. This filing ensures that stakeholders and regulatory bodies have access to accurate and up-to-date financial information.

These recent developments underscore VBI Vaccines’ dedication to advancing medical science and addressing pressing global health challenges. Through strategic partnerships, organizational changes, and ongoing research efforts, VBI Vaccines continues to make significant contributions to the field of immunization and infectious disease prevention.

https://beststocks.com/vbi-vaccines-secures-lucrative-contract-and-m/